Eli Lilly’s experimental weight-loss pill has shown promising results in a clinical trial, helping patients with type 2 diabetes shed significant weight without serious liver damage or other side effects. According to the findings, published in the New England Journal of Medicine, the highest dose of the drug led to a 7.6% body weight loss over 40 weeks. This outcome suggests that Lilly’s medicine may have blockbuster potential in its competition with Novo Nordisk A/S, and provides relief from concerns about earlier attempts at developing potent weight-loss pills.
Source: https://www.bloomberg.com/news/articles/2025-06-21/lilly-obesity-pill-to-rival-shots-holds-up-to-scrutiny-in-trial